Clark Estates Inc. NY Reduces Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Clark Estates Inc. NY decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 7.6% during the third quarter, Holdings Channel.com reports. The fund owned 12,200 shares of the biotechnology company’s stock after selling 1,000 shares during the quarter. United Therapeutics accounts for approximately 0.8% of Clark Estates Inc. NY’s investment portfolio, making the stock its 17th largest position. Clark Estates Inc. NY’s holdings in United Therapeutics were worth $4,372,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. ClariVest Asset Management LLC increased its holdings in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. USA Financial Formulas bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. Brooklyn Investment Group purchased a new position in shares of United Therapeutics during the third quarter valued at approximately $33,000. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics during the second quarter valued at approximately $30,000. Finally, Innealta Capital LLC bought a new stake in United Therapeutics in the second quarter valued at $33,000. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In other United Therapeutics news, Director Judy D. Olian sold 1,750 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the sale, the director now owns 5,655 shares in the company, valued at approximately $2,332,574.40. This represents a 23.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James Edgemond sold 7,802 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the completion of the transaction, the chief financial officer now owns 3,210 shares in the company, valued at $1,108,766.10. The trade was a 70.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 127,227 shares of company stock valued at $47,398,820. 11.90% of the stock is owned by company insiders.

United Therapeutics Price Performance

NASDAQ UTHR opened at $377.00 on Wednesday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The stock has a market capitalization of $16.83 billion, a price-to-earnings ratio of 16.56, a PEG ratio of 1.07 and a beta of 0.56. The business’s fifty day moving average price is $365.54 and its 200-day moving average price is $333.04.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same quarter last year, the firm posted $5.38 earnings per share. The firm’s revenue was up 22.9% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research reports. Jefferies Financial Group raised their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. HC Wainwright raised their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Bank of America dropped their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.